Unknown

Dataset Information

0

A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation.


ABSTRACT: In recent years, chimeric antigen receptor (CAR) T cell cancer immunotherapies have advanced substantially in the clinic. However, challenges related to safety persist; one major concern occurs when CARs trigger a response to antigen present on healthy cells (on-target, off-tumor response). A strategy to ameliorate this relies on the complex relationship between receptor affinity and signaling, such that one can engineer a CAR that is only activated by tumor cells expressing high antigen levels. Here, we developed a CAR T cell display platform with stable genomic expression and rapid functional screening based on interleukin-2 signaling. Starting with a CAR with high affinity toward its target antigen, we combined CRISPR-Cas9 genome editing and deep mutational scanning to generate a library of antigen-binding domain variants. This library was subjected to multiple rounds of selection based on either antigen binding or cell signaling. Deep sequencing of the resulting libraries and a comparative analysis revealed the enrichment and depletion of specific variants from which we selected CARs that were selectively activated by tumor cells based on antigen expression levels. Our platform demonstrates how directed evolution based on functional screening and deep sequencing-guided selection can be combined to enhance the selectivity and safety of CARs.

SUBMITTER: Di Roberto RB 

PROVIDER: S-EPMC7704745 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation.

Di Roberto Raphaël B RB   Castellanos-Rueda Rocío R   Frey Samara S   Egli David D   Vazquez-Lombardi Rodrigo R   Kapetanovic Edo E   Kucharczyk Jakub J   Reddy Sai T ST  

Molecular therapy : the journal of the American Society of Gene Therapy 20200808 12


In recent years, chimeric antigen receptor (CAR) T cell cancer immunotherapies have advanced substantially in the clinic. However, challenges related to safety persist; one major concern occurs when CARs trigger a response to antigen present on healthy cells (on-target, off-tumor response). A strategy to ameliorate this relies on the complex relationship between receptor affinity and signaling, such that one can engineer a CAR that is only activated by tumor cells expressing high antigen levels.  ...[more]

Similar Datasets

| S-EPMC5542711 | biostudies-literature
| S-EPMC6330382 | biostudies-literature
| S-EPMC10835668 | biostudies-literature
| S-EPMC5142425 | biostudies-literature
| S-EPMC8421441 | biostudies-literature
| S-EPMC7055420 | biostudies-literature
| S-EPMC5417796 | biostudies-literature
| S-EPMC5363190 | biostudies-literature
| S-EPMC9468074 | biostudies-literature
| S-EPMC10638030 | biostudies-literature